

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 18, 2024**

---

**Maravai LifeSciences Holdings, Inc.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-39725**  
(Commission  
File Number)

**85-2786970**  
(IRS Employer  
Identification No.)

**10770 Wateridge Circle Suite 200  
San Diego, California**  
(Address of principal executive offices)

**92121**  
(Zip Code)

**(858) 546-0004**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, \$0.01 par value	MRVI	The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisited financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 8.01. Other Events.**

On December 18, 2024, Maravai Intermediate Holdings, LLC (“Maravai Intermediate”), a subsidiary of Maravai LifeSciences Holdings, Inc., voluntarily pre-paid, using cash on hand, \$228 million of aggregate principal amount of the outstanding term loan (the “Term Loan”) provided under the previously disclosed Credit Agreement, dated as of October 19, 2020, among Maravai Intermediate, Cygnus Technologies, LLC (“Cygnus”), TriLink Biotechnologies, LLC (“TriLink” and together with Maravai Intermediate and Cygnus, the “Borrowers”), Maravai TopCo Holdings, LLC, each lender from time to time party thereto, and Morgan Stanley Senior Funding, Inc., as administrative agent and collateral agent (as amended, the “Credit Agreement”). After giving effect to this prepayment of principal, the aggregate remaining principal balance outstanding under the Term Loan is approximately \$300 million. There were no prepayment penalties associated with this prepayment of principal.

As of the date hereof, \$167 million in aggregate borrowing capacity remained available to the Borrowers under the revolving credit facility provided under the Credit Agreement.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MARAVAI LIFESCIENCES HOLDINGS, INC.

Date: December 18, 2024

By: /s/ Kevin M. Herde  
Name: Kevin M. Herde  
Title: Chief Financial Officer